



Erectile function following brachytherapy, external beam radiotherapy, or radical prostatectomy in prostate cancer patients

P. M. Putora · D. Engeler · S. R. Haile · N. Graf ·
K. Buchauer · H. P. Schmid · L. Plasswilm

Received: 29 April 2015 / Accepted: 20 November 2015 / Published online: 28 December 2015
© Springer-Verlag Berlin Heidelberg 2015

Abstract

Background and purpose For localized prostate cancer, treatment options include external beam radiotherapy (EBRT), radical prostatectomy (RP), and brachytherapy (BT). Erectile dysfunction (ED) is a common side-effect. Our aim was to evaluate penile erectile function (EF) before and after BT, EBRT, or RP using a validated self-administered quality-of-life survey from a prospective registry.

Material and methods Analysis included 478 patients undergoing RP ($n=252$), EBRT ($n=91$), and BT ($n=135$) with at least 1 year of follow-up and EF documented using IIEF-5 scores at baseline, 6 weeks, 6 months, 1 year, and annually thereafter.

Results Differences among treatments were most pronounced among patients with no or mild initial ED (IIEF-5 ≥ 17). Overall, corrected for baseline EF and age, BT was associated with higher IIEF-5 scores than RP (+7.8 IIEF-5 score) or EBRT (+3.1 IIEF-5 score). EBRT was associated with better IIEF-5 scores than RP (+4.7 IIEF-5 score). In patients undergoing EBRT or RP with bilateral nerve sparing (NS), recovery of EF was observed and during follow-

up, the differences to BT were not statistically significant. Overall age had a negative impact on EF preservation (corrected for baseline IIEF).

Conclusion In our series, EF was adversely affected by each treatment modality. Considered overall, BT provided the best EF preservation in comparison to EBRT or RP.

Keywords Quality of life · Erectile dysfunction · Brachytherapy · Prostatectomy · Radiotherapy

Erektile Funktion nach Brachytherapie, externer Radiotherapie oder radikaler Prostatektomie bei Prostatakrebs-Patienten

Zusammenfassung

Hintergrund und Ziel Die externe Radiotherapie (EBRT), die radikale Prostatektomie (RP) sowie die Brachytherapie (BT) stellen Behandlungsoptionen für das lokalisierte Prostatakarzinom dar. Die erektile Dysfunktion (ED) ist eine häufige Nebenwirkung dieser Therapien. Unser Ziel war es, die penile erektile Funktion (EF) vor und nach BT, EBRT und RP mit Hilfe eines validierten, vom Patienten ausgefüllten Lebensqualitätsfragebogens aus einer prospektiven Datenbank zu beurteilen.

Material und Methoden Mit einer minimalen Nachbeobachtungszeit von einem Jahr wurden 478 Patienten analysiert, die eine RP ($n=252$), EBRT ($n=91$) oder BT ($n=135$) erhalten hatten und deren EF mit dem IIEF-5-Score vor Therapie sowie nach 6 Wochen, 6 Monaten, nach einem Jahr und danach jährlich ermittelt worden sind.

Ergebnis Die größten therapiebedingten Unterschiede wurden bei Patienten ohne oder nur mit milder initialer ED beobachtet (IIEF-5 ≥ 17). Korrigiert für die EF und das Alter bei Therapie, war die BT mit höherem IIEF-5-Score

P. M. Putora and D. Engeler contributed equally to the work.

L. Plasswilm (✉) · P. M. Putora · K. Buchauer
Department of Radiation Oncology, Kantonsspital St. Gallen,
9007 St. Gallen, Switzerland
e-mail: ludwig.plasswilm@kssg.ch

D. Engeler · H. P. Schmid
Department of Urology, Kantonsspital St. Gallen,
9007 St. Gallen, Switzerland

S. R. Haile · N. Graf
Clinical Trials Unit, Kantonsspital St. Gallen,
9007 St. Gallen, Switzerland

assoziiert als die RP (+7,8 IIEF-5-Score) oder die EBRT (+3,1 IIEF-5-Score). Die EBRT war mit einem besseren IIEF-5-Score assoziiert als die RP (+4,7 IIEF-5-Score). Bei Patienten mit bilateraler nervenschonender RP oder einer EBRT wurde eine Erholung der EF beobachtet; im Verlauf war der Unterschied zur BT nicht mehr statistisch signifikant. Insgesamt hatte ein höheres Alter einen negativen Einfluss auf die Erhaltung der EF (korrigiert für Ausgangs-EF).

Schlussfolgerung In unserer Serie verschlechterte sich die EF durch alle Therapieformen. Insgesamt bot die BT die beste EF-Erhaltung verglichen mit der EBRT oder RP.

Schlüsselwörter Lebensqualität · Erektile Dysfunktion · Brachytherapie · Prostatektomie · Radiotherapie

Prostate cancer remains the most common nondermatologic cancer affecting men in the Western world [1]. The optimal management strategy for patients with newly diagnosed clinically localized prostate cancer remains a matter of debate. Because of a lack of definitive evidence demonstrating superiority in cure rates of one local treatment over another [2, 3], quality-of-life (QoL) parameters are even more important [4–6]. Functional and oncological outcomes should be considered in the evaluation of treatment success [3, 7]. Despite improvements in radiotherapy and prostatectomy, erectile dysfunction (ED) among other adverse effects, is still common [8–11]. Although local treatments focus on cure, there is a need to include ED and possible recovery of potency in their assessment [7, 12], especially since patients' decisions are driven by many factors other than cancer cure [13].

Our aim was to perform an intention-to-treat analysis from prospectively collected data from a single institution on the functional results associated with three different treatment modalities for localized prostate cancer. Patients underwent permanent I-125 low dose rate prostate brachytherapy (BT), external beam radiotherapy (EBRT), or radical prostatectomy (RP). In our study, we evaluated penile erectile function (EF) at baseline, and after treatment with a minimum follow-up of 12 months using a validated self-administered patient quality-of-life survey; we subsequently determined the impact of clinical and treatment parameters. The five-item version (IIEF-5) of the 15-item International Index of Erectile Function (IIEF; [14]) was used to quantify ED [15].

Materials and methods

A total of 478 patients with at least 12 months of follow-up and assessment of pretreatment EF determined using the IIEF-5 (range 1–25; [15, 16]) underwent LDR I-125

BT with a prescribed dose of 145 Gy, EBRT with a median dose of 72 Gy (70–78 Gy; the target of treatment being the prostate and the base of the seminal vesicles) in 3D conventional four-field technique or RP between 2005 and 2013 for mostly low–intermediate risk prostate cancer based on eligibility to these treatments and treatment decision was based on patient preference. Of the 252 radical prostatectomies, 65 were robot-assisted and the others were open. Follow-up data were collected in a prospective registry at 6 weeks, 6 months, 12 months, and annually thereafter. As a part of their follow-up patients were asked to complete an IIEF-5 questionnaire. The median follow-up was 2 years.

The IIEF-5 score was graded as very severe (1–4), severe (5–7), moderate (8–11), mild to moderate (12–16), mild (17–21), and no ED (22–25) based on the published classification [14]. In addition, a cut-off score of 17 was used to differentiate no-to-mild ED and worse ED. An age of 65 years, the median of our cohort, was used to differentiate younger from older patients.

Statistical analysis

Multinomial regression was used to explore the relationship between age, EF, and the choice of treatment. To examine the relationship between treatment and EF, linear mixed models with a random slope and intercept were used, adjusted for baseline EF and current age (<65 vs. ≥65 years). Linear models were used to examine the effect of treatment on EF scores at 1, 2, and 3 years. Adjusted confidence intervals for differences between the treatments were computed from the regression models, and adjusted using the Holm correction [17].

All analyses were performed in the R programming language (version 3.0.2; [18]). The package lme4 [19] was used to estimate the mixed models, while the multcomp package [20] was used to compute the *p*-values and confidence intervals. Box-and-whisker plots were used to represent the distribution of variables. Median values were denoted by a thick line, the box represented the upper and lower quartile. The vertical lines denote maximum and minimum values, excluding outliers. Outliers were defined as more than 3/2 of upper quartile or less than 3/2 of lower quartile and were denoted as points. The database was approved by the local ethics committee (Ethics Committee St. Gallen).

Results

A summary of baselines characteristics is provided in Table 1. Younger patients and patients with better baseline EF were more likely to undergo BT than RP and more likely to undergo RP than EBRT. There was no statistically significant interaction between age and baseline IIEF-5 score in terms of treatment choice (data not shown). Androgen

Table 1 Summary statistics at baseline by type of treatment

Variable	RP	BT	EBRT	All
<i>n</i>	252	135	91	478
Age, years (median, range)	64.5 (43.6–77.1)	63.3 (48.8–76.4)	72.0 (52.7–84.0)	65.0 (43.6–84.0)
PSA, ng/ml (median, range)	8.8 (0.2–59.0)	6.2 (0.1–20.6)	4.9 (0.1–36.0)	7.1 (0.1–59.0)
Gleason score (median, range)	7 (4–9)	6 (4–7)	7 (4 ^a –9)	6 (4–9)
T stage, <i>n</i> (%)				
T1	131 (52.0%)	89 (65.9%)	37 (41.1%)	257 (53.9%)
T2	121 (48.0%)	46 (34.1%)	45 (50.0%)	212 (44.4%)
T3	0 (0%)	0 (0%)	8 (8.9%)	8 (1.7%)
IIEF-5 score (median, range)	19.0 (1.0–25.0)	21.0 (1.0–25.0)	10.0 (1.0–25.0)	19.0 (1.0–25.0)

n number of patients, *BT* brachytherapy, *RP* radical prostatectomy, *EBRT* external beam radiotherapy. *IIEF-5* international index of erectile function.

^aIn four patients Gleason score could not be determined because prostate cancer was diagnosed based on cytology.

deprivation therapy was registered in less than 5 patients per treatment group during the first year after treatment, a few of these patients had started ADT before treatment (neoadjuvant, leading to low pre-treatment values). Only 17 patients were taking medication for ED during the whole follow-up period; 12 in the radical prostatectomy group and 5 in the brachytherapy group. The available IIEF-5 entries were 429, 358, and 275 at 1, 2 and 3 years, respectively, with similar drop-out rates across all patients groups and treatments.

While all treatment modalities were associated with a decrease in EF, the course of EF scores over time revealed a divergent effect (Fig. 1). Even after adjusting for baseline EF and age, the course of EF differed significantly depending on treatment modality. BT resulted in higher EF scores compared to RP and EBRT, while EBRT yielded higher EF scores compared to RP (Table 2 and 3).

Age was an important clinical predictor regarding the preservation of potency; thus, increasing age was associated with lower EF scores (Fig. 2). However, when analyzed separately for patients with no or mild ED at baseline (IIEF-5 \geq 17) or worse, age was a significant predictor only for patients with worse ED (IIEF-5 < 17; Table 2).

For patients with mild to no ED (IIEF-5 \geq 17) at baseline, differences in EF according to treatment modality persisted. Patients who received BT had IIEF-5 scores that were on average 9.1 points higher than those treated with RP, while patients treated with EBRT had IIEF-5 scores that were on average 6.9 points higher than those who received RP. We also observed a small, slightly nonsignificant difference between the BT and EBRT patients favoring the BT patients (Table 2).

Differences between treatments were smaller but nonetheless significant among patients with worse ED (IIEF-5 < 17) at baseline. Thus, those treated with BT had an IIEF-5 that was on average 4.6 and 2.7 points higher during overall follow-up than that in patients treated with RP and EBRT, respectively. Patients treated with EBRT had an IIEF-5 that was on average 1.8 higher than that in patients treated with RP (Table 2).

Nerve sparing (NS) was used in 45% of radical prostatectomies. Among patients treated with RP, there were no statistically significant differences in IIEF-5 between those receiving unilateral or no NS, even after adjusting for IIEF-5 at baseline and age (Table 2). However, patients receiving bilateral NS had a significantly higher IIEF-5 than patients receiving both no or unilateral NS. For patients with mild to no ED at baseline, we observed a 0.7 point higher IIEF-5 among those receiving unilateral vs no NS, and a 4.4 point higher IIEF-5 comparing patients receiving a bilateral and no NS. Among patients with a poor EF, there were no significant differences between any of the nerve sparing strategies (Table 2; Fig. 3).

For younger RP patients undergoing bilateral NS, recovery at 3 years after treatment was comparable to recovery for younger patients undergoing EBRT (Fig. 2). Thus, compared to baseline, younger RP patients undergoing bilateral NS had a mean decrease in EF of -4.4 (95% CI -8.1 to -0.8), compared to younger BT patients with a decrease of -5.3 (95% CI -6.9 to -3.6) and younger EBRT patients with a decrease of -3.8 (95% CI -13.2 to 5.6). Generally, in patients with moderate to very severe posttreatment ED no improvement was observed (Fig. 3).

When 1-, 2-, and 3-year IIEF-5 scores were compared with baseline scores a stronger preservation of EF was observed among patients undergoing EBRT or BT as compared with RP without bilateral NS, even after adjusting for baseline EF and age. At the 3-year follow-up EBRT and RP with bilateral NS were associated with worse EF than BT, but this difference was not statistically significant (Table 3).

Discussion

Our study results revealed that in a large proportion of men who undergo therapy with curative intent for localized prostate cancer, ED will occur as an adverse effect. In our series, ED was more frequent after RP relative to EBRT or BT, with a proportion of younger patients showing recovery, independent of treatment modality. Overall, the best erectile function preservation throughout follow-up, independent of age, was provided by BT. RP with bilateral NS and EBRT were associated with good recovery in young patients with good baseline EF.

Table 2 Linear mixed model with random slope and intercept for erectile function (EF) at 1.5–36 months for all patients (*upper part* of table) and RP patients only (*lower part* of table). Confidence intervals for differences between the three treatments were adjusted using the Holm correction. Values show estimate and 95% confidence interval (95% CI)

Predictor	All		No or mild ED (IIEF-5 \geq 17)		Worse ED (IIEF-5<17)	
	Estimate	95% CI	Estimate	95% CI	Estimate	95% CI
Baseline EF	0.411	0.346–0.476	0.650	0.410–0.890	0.315	0.209–0.422
Age (\geq 65)	-1.446	-2.411 to 0.482	-0.961	-2.250 to 0.327	-1.866	-3.068 to -0.665
BT vs. RP	7.799	6.564–9.034	9.092	7.506–10.677	4.573	2.877–6.269
EBRT vs. RP	4.740	3.226–6.254	6.929	4.459–9.398	1.845	0.271–3.419
BT vs. EBRT	3.059	1.348–4.771	2.163	-0.419 to 4.745	2.728	0.767–4.690
Intercept	-0.888	-0.699 to 2.155	-7.036	-12.274 to -1.797	1.9564	0.487–3.426
Predictor	All RP		No or mild ED (IIEF-5 \geq 17)		Worse ED (IIEF-5<17)	
	Estimate	95% CI	Estimate	95% CI	Estimate	95% CI
Baseline EF	0.174	0.092–0.257	0.058	-0.238 to 0.354	0.213	0.081–0.345
Age (\geq 65)	-1.358	-2.454 to -0.263	-1.114	-2.610 to 0.382	-1.764	-3.100 to -0.428
unilateral vs. no NS	0.370	-1.226 to 1.966	0.683	-1.452 to 2.818	0.013	-2.118 to 2.143
bilateral vs. no NS	3.302	1.527–5.076	4.391	2.016–6.766	0.983	-1.296 to 3.262
bilat. vs. unilateral	2.932	0.870–4.993	3.708	1.005–6.411	0.971	-1.775 to 3.716
Intercept	2.503	0.804–4.202	4.596	-1.705 to 10.898	2.707	0.913–4.501

BT brachytherapy, RP radical prostatectomy, EBRT external beam radiotherapy. IIEF-5 international index of erectile function, ED erectile dysfunction, EF erectile function, NS nerve sparing.

The optimal treatment for men with newly diagnosed clinically localized prostate cancer remains up for debate, which is due to a lack of contemporary prospective randomized studies comparing efficacy and side effects incorporating different therapies. Besides active surveillance for low-risk prostate cancers, EBRT, BT, and RP are all associated with good long-term cancer control in early stage disease [21]. During the last decade increasing attention has focused on the relative toxicities of treatments in an effort to decrease treatment-related morbidity. Patient decisions are often driven not by a focus on cancer cure, but by side effects and personal perceptions, including fear [13, 21]. This underlines the importance of outcomes beyond survival. In addition to our investigation, several studies have shown, albeit in retrospective nonrandomized series, a negative influence on sexual function after completion of prostate cancer treatment.

Sanda et al. [22] conducted a prospective multicenter evaluation assessing outcomes from 1201 patients and 625 spouses or partners before and after RP, BT, or EBRT. They noted that sexual QoL was adversely affected after each treatment as compared with baseline [22]. Besides being modality dependent, the etiology of posttreatment ED is considered to be multifactorial. The wide ranges of reported ED likely reflect differences in follow-up, patient selection, treatment technique, and the mode of data collection. However, even within trials the range of outcomes can vary considerably, in a population-based analysis by Carlsson et al. [11], odds ratios favored radiotherapy over RP for erectile dysfunction (1.56 vs. 2.29), however with an over-

lap in confidence intervals. Unfortunately, similar to cancer outcomes, little information exists in terms of randomized trial data for the evaluation of sexual QoL measures following RP, BT, or EBRT.

RP is known to cause immediate ED, after which recovery of potency typically occurs slowly or not at all [23, 24]. Unilateral nerve-sparing was performed in 21% of our patients undergoing surgery and 24% received bilateral NS. The high incidence of ED after RP in our study is in accordance with data from a large randomized trial conducted by Wilt et al. [25] who reported an incidence of 81.1% ED after nerve sparing surgery relative to 44.1% in the observational arm. In a recent paper, Montorsi et al. [26] reported data from a randomized trial regarding the effects of tadalafil treatment on recovery of EF following bilateral nerve-sparing RP. After bilateral nerve-sparing RP, 20.9, 16.9, and 19.1% of patients (mean age 57.9 years; follow-up 9–13.5 months) in the tadalafil once daily, on demand, and placebo groups, respectively, achieved IIEF-5 scores \geq 22 after a 6-week drug-free washout. An adjuvant radiotherapy trial (South Western Oncology Group 8794; [9]) indicated that only 7% of men had intact EF function postprostatectomy and pradiotherapy. Summarizing these trials, it can be assumed that about 80–95% of patients may suffer from ED immediately after RP.

ED is also a common sequelae of RT for prostate cancer, affecting approximately 35–55% of patients after EBRT [27–29] and 25–50% after BT [30–33]. Using a patient-administered validated QoL instrument, Merrick et al. [31] showed that BT-induced ED occurred in 50% of patients

Table 3 Linear model adjusted for baseline erectile function (EF) and age with EF at 12, 24, and 36 months as dependent variables. Values show estimate and confidence intervals (CI) for differences between the treatments, which were adjusted using the Holm correction

Comparison	EF at 12 months estimate (95% CI)	EF at 24 months estimate (95% CI)	EF at 36 months estimate (95% CI)
BT vs. EBRT	3.568 (1.167–5.969)	3.021 (0.300–5.743)	1.035 (–2.580 to 4.651)
BT vs. No NS	8.901 (6.927–10.876)	7.811 (5.696–9.926)	6.456 (3.775–9.138)
BT vs. unilateral NS	8.334 (5.688–10.980)	7.106 (4.044–10.168)	7.664 (3.533–11.796)
BT vs. bilateral NS	4.522 (1.427–7.617)	3.271 (–0.151 to 6.694)	2.923 (–1.459 to 7.305)
EBRT vs. no NS	5.333 (3.078–7.587)	4.790 (2.259–7.320)	5.421 (2.058–8.784)
EBRT vs. unilateral NS	4.766 (1.795–7.736)	4.085 (0.567–7.603)	6.629 (1.792–11.467)
EBRT vs. bilateral NS	0.953 (–2.462–4.369)	0.250 (–3.616–4.116)	1.888 (–3.107–6.882)

BT brachytherapy, RP radical prostatectomy, EBRT external beam radiotherapy. IIEF-5 international index of erectile function, NS nerve sparing.

at 3 years. In 2014, Ong et al. [33] reported outcomes for 366 potent (IIEF ≥ 17) patients undergoing BT with EF measured by IIEF-5. At 2 and 5 years, the prevalence of moderate–severe ED was 46 and 53%, respectively. Following permanent prostate BT, Taira et al. [34] reported a 7-year actuarial rate of potency preservation of 55.6%, with a median postimplant IIEF of 22 in potent patients. Potent patients were statistically younger, had a higher pre-implant IIEF, were less likely to be diabetic, and were more likely to report nocturnal erections [34]. A matched-pair study compared erectile dysfunction between patients undergoing dose-escalated image-guided radiotherapy (IMRT) and high dose-rate interstitial brachytherapy (HDR) revealed no overall difference in erectile function with a 2-year median follow-up [35].

Few prospective series, comparing different treatment modalities, have been reported using validated QoL instruments and incorporating pretreatment functional data. For example, Litwin et al. [36] evaluated 580 men with clinically localized prostate cancer who were undergoing RP ($n=307$), EBRT ($n=78$), or BT ($n=90$). These investigators found that men who underwent RP had worse sexual function than either radiation cohort. However, beyond 8 months after treatment the proportion of men reporting severe sexual bother did not differ significantly among treatment groups, largely due to an improvement in the sexual bother score among RP patients over time. Data from the Spanish Multicentric Study of Clinically Localized Prostate Cancer [37] showed that sexual deterioration was greater among surgical patients. Few studies have reported on long-




Fig. 1 Boxplots of IIEF-5 scores at baseline and follow-up for different treatment modalities. RP radical prostatectomy, BT brachytherapy, EBRT external beam radiotherapy

term functional outcomes involving >10 years follow-up after different treatment modalities. In 2013, the Prostate Cancer Outcomes Study [8] reported on data from a cohort comprising 1655 men in whom localized prostate cancer had been diagnosed in 1994 or 1995, between the ages of 55 and 74 years, and who had undergone either surgery (1164 men) or EBRT (491 men). Patients undergoing RP were more likely to have ED at 2 years (OR 3.46) and 5 years (OR 1.96), but no significant between-group difference was noted at 15 years. Treatment-related long-term effects on ED should be discussed with caution. The Massachusetts Male Aging Study [38] showed that the incidence rate of ED in the normal male population between 60 and 69 years of age was 4.6% per year.

In concordance with previous trials [39–41], in our study age at diagnosis was found to be an important clinical predictor for potency preservation; however, when adjusted for a baseline IIEF-5 of at least ≥ 17 (no/mild ED), age was no longer an adverse factor (Table 2). We demonstrated that preservation of EF based on baseline IIEF scores was dependent on treatment modality. At the 1-year follow-up, the treatment-related difference in occurrence of ED was most pronounced in patients with good baseline EF, favoring BT and EBRT relative to RP.

There were a number of limitations associated with the current study. First, although the data were collected prospectively, it was not a randomized trial. Second, the sample size of this prospective, single-center study was limited as compared with the sample sizes evaluated in other series, especially those with single arms. Third, the follow-up in this investigation was limited and a reliable estimation regarding EF beyond the limited follow-up time was impossible.

Improvements and developments in treatments including modern IMRT techniques and prostatectomy techniques, including their learning curves, are not addressed in this report.

Fig. 2 IIEF-5 scores for baseline (preoperative) EF and during follow-up for the different treatment modalities and nerve sparing strategies. Generally, the best EF preservation was observed in patients undergoing BT. Young patients undergoing EBRT or bilateral NS RP displayed partial EF recovery during follow-up. *EF* erectile function, *RP* radical prostatectomy, *BT* brachytherapy, *EBRT* external beam radiotherapy, *NS* nerve sparing





Fig. 3 Boxplots of IIEF scores for baseline (preoperative) erectile function and during follow-up for different treatment modalities. Patients with worse baseline EF generally did not recover. *EF* erectile function, *RP* radical prostatectomy, *BR* brachytherapy, *EBRT* external beam radiotherapy, *unilat.* unilateral, *bilat.* bilateral, *NS* nerve sparing



In addition, prospective data collection did not include other risk factors that may be associated with erectile function, such as smoking history, concomitant medication, diabetes mellitus, or other comorbidities [42–45]. Patient expectations and fears are also relevant for decision making and subjective outcome evaluation; these were not addressed [13]. Details of dose distribution known to be relevant, such as the dose to the penile bulb were also not included [46]. Currently many centers are implementing IMRT in prostate

cancer [47] which has been shown to be associated with better long-term erectile function [48]. Considering all these shortcomings, a risk for bias cannot be excluded; unknown factors may have influenced treatment decision, baseline ED as well the effect of individual treatments on EF.

Our current study also had a number of notable strengths. First, evaluation was performed using a validated QoL instrument and incorporated pretreatment functional data. In comparison to many other series we were able to include

three treatment modalities (BT, EBRT, and RP). The median follow-up was 24 months. According to the literature the follow-up should be about 24 months, after which time the development of ED tends to stabilize, at least for the following few years [8, 27, 29, 49]. Both surgical and radiotherapy patients were evaluated during the same time period with the same standardized questionnaire at the same institution.

Conclusion

In our series, relative to baseline, EF was adversely affected by each treatment modality. EF was best preserved after BT, remaining superior to EBRT and RP during 36 months of follow-up. EBRT had slightly better outcomes when compared with RP, this difference being most pronounced when patients undergoing RP did not receive bilateral nerve sparing. The treatment-related differences in occurrence of ED was most pronounced in younger patients (<65 years of age) with a good baseline EF favoring BT over other modalities. Independent of age, patients with good baseline function had the best EF preservation with BT. Although not conclusive, these data enhance our existing understanding of treatment-induced ED, which is essential when counseling patients on their treatment options.

Compliance with ethical guidelines

Conflict of interest P.M. Putora, D. Engeler, S.R. Haile, N. Graf, K. Buchauer, H.P. Schmid, and L. Passwilm state that there are no conflicts of interest.

All studies on humans described in the present manuscript were carried out with the approval of the responsible ethics committee and in accordance with national law and the Helsinki Declaration of 1975 (in its current, revised form).

References

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. *CA Cancer J Clin* 63:11–30
2. Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL (2008) Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. *Ann Intern Med* 148:435–448
3. Eble MJ (2014) Bevölkerungsbasierte Analyse von Komplikationen nach lokaler Therapie des Prostatakarzinoms. *Strahlenther Onkol* 190:594–596
4. Penson DF, Feng Z, Kuniyuki A, McClellan D, Albertsen PC, Deapen D, Gilliland F, Hoffman R, Stephenson RA, Potosky AL, Stanford JL (2003) General quality of life 2 years following treatment for prostate cancer: what influences outcomes? Results from the prostate cancer outcomes study. *J Clin Oncol* 21:1147–1154
5. Valicenti RK, Bissonette EA, Chen C, Theodorescu D (2002) Longitudinal comparison of sexual function after 3-dimensional conformal radiation therapy or prostate brachytherapy. *J Urol* 168:2499–2504 (discussion 2504). doi:10.1097/01.ju.0000038153.45342.57
6. Wyler SF, Engeler DS, Seelentag W, Ries G, Schmid HP (2009) Health-related quality of life after radical prostatectomy and low-dose-rate brachytherapy for localized prostate cancer. *Urol Int* 82:17–23. doi:10.1159/000176019
7. Salomon L, Saint F, Anastasiadis AG, Sebe P, Chopin D, Abbou CC (2003) Combined reporting of cancer control and functional results of radical prostatectomy. *Eur Urol* 44:656–660
8. Resnick MJ, Koyama T, Fan KH, Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Potosky AL, Stanford JL, Stroup AM, Van Horn RL, Penson DF (2013) Long-term functional outcomes after treatment for localized prostate cancer. *N Engl J Med* 368:436–445. doi:10.1056/NEJMoa1209978
9. Moinpour CM, Hayden KA, Unger JM, Thompson IM Jr, Redman MW, Canby-Hagino ED, Higgins BA, Sullivan JW, Lemmon D, Breslin S, Crawford ED, Southwest Oncology G (2008) Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. *J Clin Oncol* 26:112–120. doi:10.1200/JCO.2006.10.4505
10. Dolezel M, Odrázka K, Zouhar M, Vaculikova M, Sefrova J, Jansa J, Paluska P, Kohlova T, Vanasek J, Kovarik J (2015) Comparing morbidity and cancer control after 3D-conformal (70/74 Gy) and intensity modulated radiotherapy (78/82 Gy) for prostate cancer. *Strahlenther Onkol* 191:338–348
11. Carlsson S, Drevin L, Loeb S, Widmark A, Lissbrant IF, Robinson D, Johansson E, Stattin P, Fransson P (2015) Population-based study of long-term functional outcomes after prostate cancer treatment. *BJU Int*. doi:10.1111/bju.13179
12. Boorjian SA, Eastham JA, Graefen M, Guillonneau B, Karnes RJ, Moul JW, Schaeffer EM, Stief C, Zorn KC (2012) A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes. *Eur Urol* 61:664–675. doi:10.1016/j.eururo.2011.11.053
13. Anandadas CN, Clarke NW, Davidson SE, O'Reilly PH, Logue JP, Gilmore L, Swindell R, Brough RJ, Wemyss-Holden GD, Lau MW, Javle PM, Ramani VA, Wylie JP, Collins GN, Brown S, Cowan RA, North West Uro-oncology G (2011) Early prostate cancer—which treatment do men prefer and why? *BJU Int* 107:1762–1768. doi:10.1111/j.1464-410X.2010.09833.x
14. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A (1997) The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. *Urology* 49:822–830
15. Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM (1999) Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. *Int J Impot Res* 11:319–326
16. Ramanathan R, Mulhall J, Rao S, Leung R, Martinez Salamanca JI, Mandhani A, Tewari A (2007) Predictive correlation between the International Index of Erectile Function (IIEF) and Sexual Health Inventory for Men (SHIM): implications for calculating a derived SHIM for clinical use. *J Sex Med* 4:1336–1344
17. Holm S (1979) A simple sequentially rejective multiple test procedure. *Scand J Stat* 6:65–70
18. R Core Team (2013) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna
19. Bates D, Mächler M, Bolker B (2013) lme4: Linear mixed-effects models using Eigen and S4 classes. R package version 0.999999-2
20. Hothorn T, Bretz F, Westfall P (2008) Simultaneous inference in General Parametric Models. *Biom J* 50:346–336

21. van Tol-Geerdink JJ, Willem Leer J, Weijerman PC, van Oort IM, Vergunst H, van Lin EN, Alfred Witjes J, Stalmeier PF (2013) Choice between prostatectomy and radiotherapy when men are eligible for both: a randomized controlled trial of usual care vs decision aid. *BJU Int* 111:564–573. doi:10.1111/j.1464-410X.2012.11402.x
22. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, Mahadevan A, Klein E, Kibel A, Pisters LL, Kuban D, Kaplan I, Wood D, Ciezki J, Shah N, Wei JT (2008) Quality of life and satisfaction with outcome among prostate-cancer survivors. *N Engl J Med* 358:1250–1261. doi:10.1056/NEJMoa074311
23. Magheli A, Burnett AL (2009) Erectile dysfunction following prostatectomy: prevention and treatment. *Nat Rev Urol* 6:415–427. doi:10.1038/nrurol.2009.126
24. Glickman L, Godoy G, Lepor H (2009) Changes in continence and erectile function between 2 and 4 years after radical prostatectomy. *J Urol* 181:731–735. doi:10.1016/j.juro.2008.10.019
25. Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, Gingrich JR, Wei JT, Gilhooly P, Grob BM, Nsouli I, Iyer P, Cartagena R, Snider G, Roehrborn C, Sharifi R, Blank W, Pandya P, Andriole GL, Culkun D, Wheeler T (2012) Radical prostatectomy versus observation for localized prostate cancer. *N Engl J Med* 367:203–213. doi:10.1056/NEJMoa1113162
26. Montorsi F, Brock G, Stolzenburg JU, Mulhall J, Moncada I, Patel HR, Chevallier D, Krajka K, Hennes C, Dickson R, Buttner H (2014) Effects of tadalafil treatment on erectile function recovery following bilateral nerve-sparing radical prostatectomy: a Randomised Placebo-controlled Study (REACTT). *Eur Urol* 65:587–596. doi:10.1016/j.eururo.2013.09.051
27. Turner SL, Adams K, Bull CA, Berry MP (1999) Sexual dysfunction after radical radiation therapy for prostate cancer: a prospective evaluation. *Urology* 54:124–129
28. Zelefsky MJ, Cowen D, Fuks Z, Shike M, Burman C, Jackson A, Venkatramen ES, Leibel SA (1999) Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. *Cancer* 85:2460–2468
29. van der Wielen GJ, Mulhall JP, Incrocci L (2007) Erectile dysfunction after radiotherapy for prostate cancer and radiation dose to the penile structures: a critical review. *Radiother Oncol* 84:107–113. doi:10.1016/j.radonc.2007.07.018
30. Potters L, Torre T, Fearn PA, Leibel SA, Kattan MW (2001) Potency after permanent prostate brachytherapy for localized prostate cancer. *Int J Radiat Oncol Biol Phys* 50:1235–1242
31. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Anderson RL, Kurko BS, Lief JH, Allen ZA (2005) Erectile function after prostate brachytherapy. *Int J Radiat Oncol Biol Phys* 62:437–447. doi:10.1016/j.ijrobp.2004.10.001
32. Stone NN, Stock RG (2007) Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years. *Urology* 69:338–342. doi:10.1016/j.urology.2006.10.001
33. Ong WL, Hindson BR, Beaufort C, Pharoah P, Millar JL (2014) Long-term erectile function following permanent seed brachytherapy treatment for localized prostate cancer. *Radiother Oncol* 112:72–76. doi:10.1016/j.radonc.2014.04.017
34. Taira AV, Merrick GS, Galbreath RW, Butler WM, Wallner KE, Kurko BS, Anderson R, Lief JH (2009) Erectile function durability following permanent prostate brachytherapy. *Int J Radiat Oncol Biol Phys* 75:639–648. doi:10.1016/j.ijrobp.2008.11.058
35. Marina O, Warner J, Ye H, Grills IS, Shah C, Wallace M, Gustafson GS, Brabbins DS, Martinez AA, Krauss DJ (2014) An age-corrected matched-pair study of erectile function in patients treated with dose-escalated adaptive image-guided intensity-modulated radiation therapy vs. high-dose-rate brachytherapy for prostate cancer. *Brachytherapy* 13:163–168. doi:10.1016/j.brachy.2013.10.006
36. Litwin MS, Gore JL, Kwan L, Brandeis JM, Lee SP, Withers HR, Reiter RE (2007) Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. *Cancer* 109:2239–2247. doi:10.1002/encr.22676
37. Pardo Y, Guedea F, Aguilo F, Fernandez P, Macias V, Marino A, Hervas A, Herruzo I, Ortiz MJ, Ponce de Leon J, Craven-Bratle J, Suarez JF, Boladeras A, Pont A, Ayala A, Sancho G, Martinez E, Alonso J, Ferrer M (2010) Quality-of-life impact of primary treatments for localized prostate cancer in patients without hormonal treatment. *J Clin Oncol* 28:4687–4696. doi:10.1200/JCO.2009.25.3245
38. Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB (2000) Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. *J Urol* 163:460–463
39. Nishimura S, Yorozu A, Ohashi T, Sakayori M, Yagi Y, Nishiyama T, Saito S, Shiraishi Y, Yoshida K, Toya K, Shigematsu N (2013) Five-year potency preservation after iodine-125 prostate brachytherapy. *Int J Clin Oncol*. doi:10.1007/s10147-013-0632-8
40. Matsushima M, Kikuchi E, Maeda T, Nakashima J, Sugawara A, Ando T, Mizuno R, Nagata H, Miyajima A, Shigematsu N, Oya M (2013) A prospective longitudinal survey of erectile dysfunction in patients with localized prostate cancer treated with permanent prostate brachytherapy. *J Urol* 189:1014–1018. doi:10.1016/j.juro.2012.09.086
41. Alemozaffar M, Regan MM, Cooperberg MR, Wei JT, Michalski JM, Sandler HM, Hembroff L, Sadetsky N, Saigal CS, Litwin MS, Klein E, Kibel AS, Hamstra DA, Pisters LL, Kuban DA, Kaplan ID, Wood DP, Ciezki J, Dunn RL, Carroll PR, Sanda MG (2011) Prediction of erectile function following treatment for prostate cancer. *JAMA* 306:1205–1214. doi:10.1001/jama.2011.1333
42. Rizvi K, Hampson JP, Harvey JN (2002) Do lipid-lowering drugs cause erectile dysfunction? A systematic review. *Fam Pract* 19:95–98
43. Fonseca V, Seftel A, Denne J, Fredlund P (2004) Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials. *Diabetologia* 47:1914–1923
44. McVary KT, Carrier S, Wessells H (2001) Smoking and erectile dysfunction: evidence based analysis. *J Urol* 166:1624–1632
45. Greenstein A, Chen J, Miller H, Matzkin H, Villa Y, Braf Z (1997) Does severity of ischemic coronary disease correlate with erectile function? *Int J Impot Res* 9:123–126
46. Magli A, Giangreco M, Crespi M, Negri A, Ceschia T, De Giorgi G, Titone F, Parisi G, Fongione S (2012) Erectile dysfunction after prostate three-dimensional conformal radiation therapy. *Strahlenther Onkol* 188:997–1002
47. Panje CM, Dal Pra A, Zilli T, D RZ, Papachristofilou A, Herrera FG, Matzinger O, Plasswilm L, Putora PM (2015) Consensus and differences in primary radiotherapy for localized and locally advanced prostate cancer in Switzerland: a survey on patterns of practice. *Strahlenther Onkol*. doi:10.1007/s00066-015-0849-8
48. Pinkawa M, Piroth MD, Holy R, Djukic V, Klotz J, Krenkel B, Eble MJ (2011) Combination of dose escalation with technological advances (intensity-modulated and image-guided radiotherapy) is not associated with increased morbidity for patients with prostate cancer. *Strahlenther Onkol* 187:479–484. doi:10.1007/s00066-011-2249-z
49. van der Wielen GJ, van Putten WL, Incrocci L (2007) Sexual function after three-dimensional conformal radiotherapy for prostate cancer: results from a dose-escalation trial. *Int J Radiat Oncol Biol Phys* 68:479–484. doi:10.1016/j.ijrobp.2006.12.015